EpiCast Report: Diabetic Neuropathy - Epidemiology Forecast to 2022

Summary

Diabetic neuropathy affects an estimated 50% of patients with diabetes and is one of the leading causes of morbidity in diabetic patients, often leading to foot ulcerations or amputation. Diabetic neuropathy is clinically defined as “the presence of symptoms and/or signs of peripheral nerve dysfunction in people with diabetes after the exclusion of other causes” (Argoff et al., 2006; Boulton et al., 1998).


According to the epidemiologic literature, poor glycemic control, age, duration of diabetes, and obesity are risk factors for diabetic neuropathy (Abbott et al., 2011; Adler et al., 1997; Argoff et al., 2006; Tesfaye and Selvarajah, 2012). However, diabetic neuropathy is considered to be part of the natural progression of diabetes as a microvascular complication of the disease.


GlobalData epidemiologists forecast that the total prevalent cases of diabetic neuropathy in the diagnosed diabetic population in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan) will increase from 13,842,033 cases in 2012 to 19,783,289 cases in 2022 at an Annual Growth Rate (AGR) of 4.29%. Throughout the forecast period, the US will have the highest number of total prevalent diabetic neuropathy cases in the diagnosed diabetic population, with approximately 45% of the cases. The increase in the number of total prevalent cases of diabetic neuropathy in the 7MM is the result of changing population demographics and GlobalData’s predicted increase in the diagnosed prevalent cases of diabetes in the 7MM.

Scope

- The diabetic neuropathy EpiCast Report provides an overview of the risk factors and epidemiological trends for diabetic neuropathy in the seven major markets (6MM) (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiological forecast of the total prevalent cases of diabetic neuropathy in the diagnosed diabetic population segmented by age, (adults over the age of 40 years), sex, and the proportion of comorbid hypertension prevalent case in these markets.
- The diabetic neuropathy epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global DFU market.
- Quantify patient populations in the global diabetic neuropathy market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for diabetic neuropathy therapeutics in each of the markets covered.

Table Of Contents

Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
3 Epidemiology 8
3.1 Disease Background 8
3.2 Risk Factors and Comorbidities 9
3.3 Global Trends 9
3.3.1 US 10
3.3.2 5EU 11
3.3.3 Japan 12
3.4 Epidemiological Forecast for Diabetic Neuropathy (2012-2022) 13
3.4.1 Forecast Methodology 13
3.4.2 Sources Used 14
3.4.3 Sources Not Used 17
3.4.4 Forecast Assumptions and Methods — Diagnosed Prevalent Cases of Diabetes 19
3.4.5 Forecast Assumptions and Methods — Diabetic Neuropathy 23
3.5 Epidemiology Forecast for Diabetic Neuropathy (2012-2022) 25
3.5.1 Diabetic Neuropathy 25
3.5.2 Total Prevalent Cases of Diabetic Neuropathy by Age 27
3.5.3 Total Prevalent Cases of Diabetic Neuropathy by Sex 29
3.5.4 Total Prevalent Cases of Diabetic Neuropathy, Comorbid Hypertension 31
3.6 Discussion 32
3.6.1 Conclusions on Epidemiological Trends 32
3.6.2 Limitations of the Analysis 34
3.6.3 Strengths of the Analysis 35
4 Appendix 36
4.1 Bibliography 36
4.2 About the Authors 41
4.2.1 Epidemiologists 41
4.2.2 Reviewers 41
4.2.3 Global Director of Epidemiology and Health Policy 42
4.2.4 Global Head of Healthcare 42
4.3 About GlobalData 43
4.4 About EpiCast 43
4.5 Disclaimer 43



List of Tables

Table 1: Neuropathic Pain Descriptor Terms 8
Table 2: 7MM, Sources of Diabetic Neuropathy Total Prevalence Data 13
Table 3: 7MM, Excluded Sources of Diabetic Neuropathy Total Prevalence Data 17
Table 4: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, Both Sexes, Ages ? 40 Years, N, 2012-2022 25
Table 5: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, Both Sexes, by Age, N, Row (%), 2012 27
Table 6: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, by Sex, Ages ? 40 Years, N, Row (%), 2012 29



List of Figures

Figure 1: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, Both Sexes, Ages ? 40 Years, N, 2012-2022 26
Figure 2: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, Both Sexes, by Age, N, 2012 28
Figure 3: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, by Sex, Ages ? 40 Years, N, 2012 30
Figure 4: 7MM, Comorbid Hypertension in Diabetic Neuropathy Cases (N), Both Sexes, Ages 40+, 2012 31

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Shadi

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022

  • $ 9 995
  • Industry report
  • March 2014
  • by Global Data

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022 Summary Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, ...

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 9 995
  • Industry report
  • April 2014
  • by Global Data

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most ...

Multiple Sclerosis (MS) Drugs and Biologics : Technologies and Global Markets

Multiple Sclerosis (MS) Drugs and Biologics : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This BCC Research study offers an overview of the multiple sclerosis (MS) disease-modifying product market, including regulatory issues accompanied by detailed analyses and forecasts by product. Its main ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.